A safety and feasibility trial of ¹³¹ I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.

ABSTRACT:

Introduction

¹³¹ I-meta-iodobenzylguanidine (¹³¹ I-MIBG) is effective in relapsed neuroblastoma. The Children's Oncology Group (COG) conducted a pilot study (NCT01175356) to assess tolerability and feasibility of induction chemotherapy followed by ¹³¹ I^- MIBG therapy and myeloablative busulfan/melphalan (Bu/Mel) in patients with newly diagnosed high-risk neuroblastoma.

Methods

Patients with MIBG-avid high-risk neuroblastoma were eligible. After the first two patients to receive protocol therapy developed severe sinusoidal obstruction syndrome (SOS), the trial was re-designed to include an ¹³¹ I-MIBG dose escalation (12, 15, and 18 mCi/kg), with a required 10-week gap before Bu/Mel administration. Patients who completed i

SUBMITTER: Weiss BD 

PROVIDER: S-EPMC9150928 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature